Affordable Access

deepdyve-link
Publisher Website

Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.

Authors
  • Schett, Georg
  • Wollenhaupt, Jurgen
  • Papp, Kim
  • Joos, Rik
  • Rodrigues, Jude F
  • Vessey, Adele R
  • Hu, ChiaChi
  • Stevens, Randall
  • de Vlam, Kurt L
Type
Published Article
Journal
Arthritis & Rheumatism
Publisher
Wiley (John Wiley & Sons)
Publication Date
Oct 01, 2012
Volume
64
Issue
10
Pages
3156–3167
Identifiers
DOI: 10.1002/art.34627
PMID: 22806399
Source
Medline
License
Unknown

Abstract

Treatment with apremilast at a dosage of 20 mg twice per day or 40 mg once per day demonstrated efficacy in comparison with placebo and was generally well tolerated in patients with active PsA. The balance of efficacy, tolerability, and safety supports further study of apremilast in PsA.

Report this publication

Statistics

Seen <100 times